PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII)
A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8047
- Medical University Graz, department of obstetrics and gynecology
-
Vienna, Austria, 1090
- Medical University Vienna, department of obstetrics and gynecology
-
-
-
-
-
Bruxelles, Belgium, 1200
- Cliniques universitaires Saint-Luc
-
Liège, Belgium, 4000
- CHR de la Citadelle
-
Yvoir, Belgium, 5530
- Cliniques Universitaires UCL de Mont-Godinne
-
-
-
-
-
Bialystok, Poland, 15-224
- Prywatna Klinika Polozniczo-Ginekologiczna
-
Gdańsk, Poland, 80-895
- INVICTA Sp. Z o.o.
-
Katowice, Poland, 40-724
- Private practice
-
Lodz, Poland, 90-602
- Private practice
-
Lublin, Poland, 20-081
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Klinika Ginekologii Onkologicznej i Ginekologii
-
Warszawa, Poland, 00-815
- Private practice
-
Warszawa, Poland, 02-066
- Private practice
-
Warszawa, Poland, 02-507
- Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej
-
Wroclaw, Poland, 50-369
- Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa
-
-
-
-
-
Barcelona, Spain, 08028
- Institut Universitari Dexeus Departamento de Ginecología
-
Barcelona, Spain, 08035
- Hospital Universitario Hebron, gynecology department
-
Barcelona, Spain, 08036
- Hospital Clinic i provincial de Barcelona, gynecology department
-
Ciudad Real, Spain, 13005
- Hospital General de Ciudad Real Gynecology
-
Guadalajara, Spain, 19002
- Hospital Universitario de Guadalajara Consultas de Ginecología (Planta 0)
-
Lugo, Spain, 27002
- Clinica Ginecologica CEOGA, departamento de Ginecologia
-
Madrid, Spain, 28009
- Private pratice
-
Madrid, Spain, 28041
- Hospital universitario 12 de Octubre, departamento de ginecologia
-
Malaga, Spain, 29010
- CHIP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is a pre-menopausal woman aged between 18 and 48 years inclusive.
- Subject with a Body Mass Index ≥18 and ≤40.
- Subject with myomatous uterus size < 16 weeks.
- Subject must have at least one uterine myoma of at least 3 cm diameter in size and no myoma larger than 10 cm diameter diagnosed by ultrasound.
- Subject complained of strong uterine bleeding.
- Subject is eligible for hysterectomy or myomectomy.
- Females of childbearing potential have to practice a non-hormonal method of contraception.
Exclusion Criteria:
- Subject has a history of or current uterus, cervix, ovarian or breast cancer.
- Subject has a history of endometrium hyperplasia or adenocarcinoma in a biopsy performed within the past 6 months or similar lesions in the screening biopsy.
- Subject has a known severe coagulation disorder.
- Subject has a history of treatment for myoma with a SPRM, including ulipristal acetate.
- Subject has abnormal hepatic function at study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
|
PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
Other Names:
|
|
Experimental: B
Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
|
PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy endpoints
Time Frame: From baseline to end of PGL4001 treatment (3months treatment) and to approximately 2 weeks after double blind treatment with progestin/placebo.
|
Investigate efficacy of PGL4001 on uterine bleeding (% of subjects in amenorrhea at end of PGL4001 treatment), myoma size (transvaginal ultrasound), pain (short Mc Gill questionnaire) and quality of life (specific UFS-QoL questionnaire and general EQ-5D questionnaire).
|
From baseline to end of PGL4001 treatment (3months treatment) and to approximately 2 weeks after double blind treatment with progestin/placebo.
|
|
Number and proportion of subjects experiencing open label treatment-emergent adverse events
Time Frame: From baseline to end of PGL4001 treatment (3months treatment)
|
From baseline to end of PGL4001 treatment (3months treatment)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Muscle Tissue
- Leiomyoma
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Progestins
- Ulipristal acetate
Other Study ID Numbers
Other Study ID Numbers
- PGL09-026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.